

- and metastasis. *Cancer Res* 2013;73:3716-24.
26. Shi Y, Ma Z, Cheng Q, Wu Y, Parris AB, Kong L, et al. FGFR1 overexpression renders breast cancer cells resistant to metformin through activation of IRS1/ERK signaling. *Biochim Biophys Acta Mol Cell Res* 2021;1868:118877.
 27. Han ZJ, Feng YH, Gu BH, Li YM, Chen H. The post-translational modification, SUMOylation, and cancer (Review). *Int J Oncol* 2018;52:1081-94.
 28. Saha G, Sarkar S, Mohanta PS, Kumar K, Chakrabarti S, Basu M, et al. USP7 targets XIAP for cancer progression: Establishment of a p53-independent therapeutic avenue for glioma. *Oncogene* 2022;41:5061-75.
 29. Zheng N, Chu M, Lin M, He Y, Wang Z. USP7 stabilizes EZH2 and enhances cancer malignant progression. *Am J Cancer Res* 2020;10:299-313.
 30. Carreira LD, Oliveira RI, Moreira VM, Salvador JAR. Ubiquitin-specific protease 7 (USP7): an emerging drug target for cancer treatment. *Expert Opin Ther Targets* 2023;27:1043-58.
 31. Li B, Wang J, Liao J, Wu M, Yuan X, Fang H, et al. YY1 promotes pancreatic cancer cell proliferation by enhancing mitochondrial respiration. *Cancer Cell Int* 2022;22:287.
 32. Tseng HY, Chen YA, Jen J, Shen PC, Chen LM, Lin TD, et al. Oncogenic MCT-1 activation promotes YY1-EGFR-MnSOD signaling and tumor progression. *Oncogenesis* 2017;6:e313.

Non-commercial use only

Received: 16 April 2024. Accepted: 3 July 2024.

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License (CC BY-NC 4.0).

©Copyright: the Author(s), 2024

Licensee PAGEPress, Italy

European Journal of Histochemistry 2024; 68:4048

doi:10.4081/ejh.2024.4048

Publisher's note: all claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.